High-dose single-fraction IMRT versus fractionated external beam radiotherapy for patients with spinal bone metastases: study protocol for a randomized controlled trial

Trials. 2015 Jun 9:16:264. doi: 10.1186/s13063-015-0761-7.

Abstract

Background: Stereotactic body radiation therapy (SBRT)using intensity-modulated radiotherapy (IMRT) can be a safe modality for treating spinal bone metastasis with enhanced targeting accuracy and an effective method for achieving good tumor control and a rigorous pain response.

Methods/design: This is a single-center, prospective randomized controlled trial to evaluate pain relief after RT and consists of two treatment groups with 30 patients in each group. One group will receive single-fraction intensity-modulated RT with 1 × 24 Gy, and the other will receive fractionated RT with 10 × 3 Gy. The target parameters will be measured at baseline and at 3 and 6 months after RT.

Discussion: The aim of this study is to evaluate pain relief after RT in patients with spinal bone metastases by means of two different techniques: stereotactic body radiation therapy and fractionated RT. The primary endpoint is pain relief at the 3-month time-point after RT. Secondly, quality of life, fatigue, overall and bone survival, and local control will be assessed.

Trial registration: ClinicalTrials.gov identifier NCT02358720 (June 2, 2015).

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Protocols
  • Dose Fractionation, Radiation*
  • Fatigue / etiology
  • Fatigue / psychology
  • Germany
  • Humans
  • Pain / diagnosis
  • Pain / etiology
  • Pain / radiotherapy*
  • Pain Measurement
  • Palliative Care
  • Prospective Studies
  • Quality of Life
  • Radiosurgery / adverse effects
  • Radiosurgery / methods*
  • Radiotherapy, Intensity-Modulated / adverse effects
  • Radiotherapy, Intensity-Modulated / methods*
  • Research Design
  • Spinal Neoplasms / complications
  • Spinal Neoplasms / mortality
  • Spinal Neoplasms / radiotherapy*
  • Spinal Neoplasms / secondary
  • Time Factors
  • Treatment Outcome

Associated data

  • ClinicalTrials.gov/NCT02358720